Table 3:

Adjust Outcomes after Hepatic Encephalopathy in a Cohort of 2,184 Privately Insured Persons with Cirrhosis

		Death		Hospital days
Baseline Variable	Baseline Value	Adjusted sHR (95% CI)	P-Value	Adjusted IRR (95%CI)	P-Value
Age (per year)	61 ± 14	1.03 (1.02–1.04)	<0.001	1 (0.99–1.01)	0.963
Male	1334 (57%)	1.13 (0.94–1.36)	0.183	0.96 (0.84–1.11)	0.608
White Race (vs others)	1460 (62%)	0.97 (0.81–1.15)	0.183	1.07 (0.93–1.23)	0.364
Cirrhosis Etiology
Alcohol	1208 (51%)	0.85 (0.71–1.01)	0.069	0.9 (0.78–1.04)	0.139
Diabetes mellitus	1264 (54%)	0.88 (0.74–1.06)	0.189	1.15 (0.99–1.35)	0.068
Hepatitis B	199 (8%)	0.75 (0.54–1.04)	0.086	0.91 (0.71–1.16)	0.434
Hepatitis C	1004 (43%)	0.86 (0.71–1.04)	0.114	0.91 (0.79–1.06)	0.231
Morbid obesity	344 (15%)	0.86 (0.66–1.12)	0.266	1.19 (0.98–1.44)	0.076
Gastroenterology Consult	1998 (85%)	1.23 (0.94–1.61)	0.127	1.11 (0.92–1.34)	0.266
Lactulose	863 (37%)	0.43 (0.36–0.52)	<0.001	0.44 (0.38–0.5)	<0.001
Rifaximin	492 (21%)	0.58 (0.46–0.72)	<0.001	0.56 (0.47–0.66)	<0.001
Ascites	887 (38%)	1.15 (0.95–1.39)	0.165	1.13 (0.98–1.3)	0.091
Variceal bleeding	169 (7%)	0.96 (0.67–1.37)	0.812	0.8 (0.61–1.04)	0.096
Transjugular intrahepatic portosystemic shunt	59 (3%)	1.03 (0.65–1.61)	0.913	1.41 (0.92–2.17)	0.115
Hepatocellular Carcinoma	255 (11%)	1.7 (1.31–2.20)	<0.001	1.49 (1.2–1.86)	<0.001
Charlson Comorbidity Index (CCI; relative to CCI 1)
CCI=2	356 (15%)	1.46 (0.91–2.35)	0.117	0.77 (0.56–1.08)	0.128
CCI=≥3	1864 (79%)	1.1 (0.8–1.50)	0.06	0.94 (0.66–1.34)	0.736
MELD-Na	14 ± 12	1.05 (1.04–1.07)	<0.001	1.05 (1.03–1.06)	<0.001
Albumin g/dL	3.3 ± 3.3	0.71 (0.61–0.83)	<0.001	0.83 (0.74–0.93)	0.001
Platelet count	147 ± 122	1 (1.00–1.002)	0.011	1.002 (1.001–1.003)	<0.001

MELD-Na (Model for Endstage Liver Disease – Sodium), TIPS =. sHR = subhazard distribution ratio (accounts for the competing risk of death)